SIGA

SIGA Technologies, Inc. - Q3 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the development and sale of TPOXX® (tecovirimat), an antiviral drug for the treatment of smallpox. The company primarily sells oral and intravenous (IV) formulations of TPOXX® to the U.S. Government (via BARDA and DoD contracts) and international governments.

Key Financial Metrics

Liquidity and Debt: The company reported no long-term debt. Total liabilities were $25.9 million, primarily consisting of deferred revenue ($13.7 million) and accrued expenses. Cash decreased by approximately $50.9 million year-to-date, largely due to a special dividend payment of $42.7 million and income tax payments.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 8% in Q3 2024 compared to Q3 2023 and surged 144% year-to-date. This growth is driven by significant deliveries of oral and IV TPOXX® to the U.S. Strategic National Stockpile under the 19C BARDA Contract.
• Profitability Turnaround: The company returned to profitability in Q3 2024, reporting net income of $1.3 million compared to a net loss of $0.4 million in the prior year quarter. Year-to-date, the company generated $13.5 million in net income versus a $4.2 million loss in 2023.
• Cost Structure: Cost of sales increased significantly year-to-date ($17.2 million vs. $3.0 million) due to higher volumes of product delivery. However, R&D expenses decreased by $4.8 million year-to-date due to the completion of billable activities under the PEP Label Expansion R&D Contract.
• Shareholder Returns: In Q2 2024, the company paid a special cash dividend of $0.60 per share (approx. $43 million total), a significant cash outflow not present in the same period of 2023.

Outlook, Risks, and Management Commentary

• Contract Status: The 19C BARDA Contract contemplates up to $602.5 million in payments. As of September 30, 2024, $519.6 million in options have been exercised. Unexercised options totaling $31.2 million remain, which BARDA may exercise at its sole discretion.
• Recent Deliveries: In October 2024 (post-period), the company delivered $51.2 million of oral TPOXX® and $8.5 million of IV TPOXX® to the Strategic National Stockpile.
• Regulatory Pipeline: The company is targeting a Supplemental NDA filing for a smallpox post-exposure prophylaxis (PEP) indication in Q3 2025. A new drug application for oral TPOXX® was filed in Japan, with a decision expected by Q1 2025.
• Clinical Trials: The PALM 007 trial in the DRC for mpox treatment did not meet its primary endpoint for the overall population but showed improvement in patients with severe disease or early symptom onset. Data from this and other trials may support a future mpox label expansion.
• Risks: Key risks include the U.S. Government's discretion to exercise or terminate contract options, supply chain disruptions, and the uncertainty of regulatory approvals for new indications (mpox, PEP).

Investor Verification Checklist

• Contract Option Exercise: Verify the status of the remaining $31.2 million in unexercised options under the 19C BARDA Contract, as future revenue depends on BARDA's discretion.
• Deferred Revenue: Confirm the recognition timeline for the $13.7 million in deferred IV TPOXX® revenue recorded as of September 30, 2024.
• Cash Burn vs. Dividends: Assess the sustainability of the dividend policy given the $50.9 million cash decrease year-to-date and the reliance on government contract payments for liquidity.
• International Sales Mix: Monitor the shift in international sales strategy following the amendment of the International Promotion Agreement with Meridian Medical Technologies, effective June 1, 2024.
• Regulatory Milestones: Track the progress of the PALM 007 trial data analysis and the timeline for the PEP Supplemental NDA filing targeted for late 2025.